Latest Breaking News On - Cure pharma - Page 7 : comparemela.com

AlzeCure announces positive data from clinical study with ACD440 AlzeCure announces positive data from clinical study with ACD440 AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received positive results from the phase Ib clinical study with its drug candidate ACD440 for neuropathic pain. The results, presented slightly ahead of plan, demonstrate that ACD440, a TRPV1 antagonist and AlzeCure’s drug candidate for neuropathic pain within the company s Painless platform, was able to demonstrate positive proof-of-mechanism data, showing analgesic efficacy in man. The observed effects with ACD440 were highly significant over placebo. Also, it was well tolerated as a topical gel on human skin which indicates good suitability for further clinical devel

Alzecure pharmaJohan sandinCure pharmaNasdaq first north premier growth marketஜோஹன் சாண்டின்குணப்படுத்த பார்மாநாஸ்டாக் முதல் வடக்கு ப்ரிமியர் வளர்ச்சி சந்தை